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Abstract
Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the
infection, but treatment is life-long and has high costs and unpredictable long-term side effects. The profound suppression
of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of
extinction. Consequently, more patients could be cured by suppressing HBV replication further using a new drug in
combination with the nucleos(t)ide analogs. The HBV ribonuclease H (RNAseH) is a logical drug target because it is the
second of only two viral enzymes that are essential for viral replication, but it has not been exploited, primarily because it is
very difficult to produce active enzyme. To address this difficulty, we expressed HBV genotype D and H RNAseHs in E. coli
and enriched the enzymes by nickel-affinity chromatography. HBV RNAseH activity in the enriched lysates was characterized
in preparation for drug screening. Twenty-one candidate HBV RNAseH inhibitors were identified using chemical structure-
activity analyses based on inhibitors of the HIV RNAseH and integrase. Twelve anti-RNAseH and anti-integrase compounds
inhibited the HBV RNAseH at 10 mM, the best compounds had low micromolar IC50 values against the RNAseH, and one
compound inhibited HBV replication in tissue culture at 10 mM. Recombinant HBV genotype D RNAseH was more sensitive
to inhibition than genotype H. This study demonstrates that recombinant HBV RNAseH suitable for low-throughput antiviral
drug screening has been produced. The high percentage of compounds developed against the HIV RNAseH and integrase
that were active against the HBV RNAseH indicates that the extensive drug design efforts against these HIV enzymes can
guide anti-HBV RNAseH drug discovery. Finally, differential inhibition of HBV genotype D and H RNAseHs indicates that viral
genetic variability will be a factor during drug development.
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Introduction
Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates
by reverse transcription [1]. It chronically infects.350 million people
world-wide and kills up to 1.2 million patients annually by inducing
liver failure and liver cancer [2–4]. Reverse transcription is catalyzed
by a virally-encoded polymerase that has two enzymatic activities: a
DNA polymerase that synthesizes new DNA and a ribonuclease H
(RNAseH) that destroys the viral RNA after it has been copied into
DNA [1,5]. Both activities are essential for viral replication.
HBV infections are treated with interferon a or one of five
nucleos(t)ide analogs [6–8]. Interferon a leads to sustained clinical
improvement in 20–30% of patients, but the infection is very
rarely cleared [1,3,9]. The nucleos(t)ide analogs are used more
frequently than interferon. They inhibit DNA synthesis and
suppress viral replication by 4–5 log10 in up to 70–90% patients,
often to below the standard clinical detection limit of 300–400
copies/ml [10–12]. However, treatment eradicates the infection as
measured by loss of the viral surface antigen (HBsAg) from the
serum in only 3–6% of patients even after years of therapy [10–
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13]. Antiviral resistance was a major problem with the earlier
nucleos(t)ide analogs, but resistance to the newer drugs entecavir
and tenofovir is very low [6,14,15]. This has converted hepatitis B
from a steadily worsening disease into a controllable condition for
most individuals [16]. The cost of this control is indefinite
administration of the drugs (probably life-long; [7]), with ongoing
expenses of $400–600/month [17,18] and unpredictable adverse
effects associated with decades-long exposure to the drugs.
The key form of the HBV genome in cells that must be
eliminated to clear the infection is the nuclear episomal covalently-
closed circular DNA (cccDNA) that is the template for transcrip-
tion of all HBV RNAs [19]. Following reverse transcription in the
cytoplasm, newly synthesized genomes can either be enveloped
and secreted from the cell as virions, or they can be transported
into the nucleus to replenish the cccDNA pool (Fig. 1) [19,20].
Transfer of newly synthesized viral genomes into the nucleus via
‘‘recycling’’ is the default pathway, and virion secretion occurs
only if the cccDNA pool is large enough to support adequate
synthesis of the HBsAgs.
The cccDNA pool is very stable, but nucleos(t)ide therapy can
suppress cccDNA levels in the liver by ,1 log10 after 1–2 years
[21–23]. The indefinite persistence of the cccDNA even in patients
whose HBV titres in serum have been suppressed below the limit
of clinical detection by the nucleos(t)ide analogs is due to residual
viral replication, leading to replenishment of the cccDNA pool by
a combination of intracellular recycling and low-level infection of
new cells [24,25]. The sequential accumulation of resistance
mutations during nucleos(t)ide therapy confirms that cccDNA
maintenance by residual viral replication occurs in the absence of
clinically detectable viremia [15,26,27]. A recent genetic analysis
of HBV DNA in the liver explicitly demonstrated that low levels of
cccDNA replenishment occurs even when nucleos(t)ide analog
therapy has reduced viral titres below the clinical detection limit
[24].
RNAseH enzymes hydrolyze RNA in an RNA:DNA heterodu-
plex [28]. They belong to the nucleotidyl transferase superfamily
whose members share a similar protein fold and presumably have
similar enzymatic mechanisms [29]. This family includes E. coli
RNAseH I and II [30], DNA transposases including the Tn5
transposase [31], retroviral integrases including the HIV integrase
[32], the RuvC Holliday junction resolvase [33], the Argonaute
RNAse [34], and human RNAseH 1 and 2 [35,36]. The canonical
RNAseH structure contains about 100 aa including four con-
served carboxylates (the ‘‘DEDD’’ motif) that coordinate two
divalent cations [37]. The RNAseH mechanism is believed to
involve both divalent cations [29,38,39], although a one-ion
mechanism has also been proposed [40,41]. The HBV RNAseH
domain shares low but recognizable (,20%) sequence identity
with the RNAseH domains of reverse transcriptases and other
retro-elements [42–44]. Manually optimizing alignment of the
HBV RNAseH and the HIV-1 RNAseH yielded 23% identity and
33% similarity (Fig. 2). A similar alignment between the HBV
RNAseH and the HIV integrase revealed 19% identity and 33%
similarity.
The HBV RNAseH is encoded at the carboxy-terminus of the
viral polymerase protein that also encodes the viral DNA
polymerase activity (reverse transcriptase). The high hydropho-
bicity of the HBV polymerase and its existence as a complex with
host chaperones [45] have severely restricted study of the HBV
RNAseH. Furthermore, we demonstrated that the RNAseH in its
native context within the polymerase protein is unable to accept
exogenous heteroduplex substrates [46], analogous to the inability
of the DNA polymerase active site to engage exogenous primer-
templates [47]. Consequently, most of our limited knowledge of
the RNAseH comes from mutational studies of the viral genome in
the context of viral replication conducted by us and others [48–
53]. These restrictions have prevented biochemical characteriza-
tion of the RNAseH and blocked biochemical screens for anti-
HBV RNAseH drugs to date.
A few reports of recombinant forms of the hepadnaviral
RNAseH exist. Wei and co-workers [54] expressed the HBV
RNAseH domain in E. coli and purified it by denaturing nickel-
affinity chromatography. Following refolding, they found an
RNAse activity. Lee et al. [55] expressed the HBV RNAseH
domain in E. coli as a dual maltose-binding protein/hexahistidine
fusion and purified soluble protein by two-step affinity chroma-
tography; this enzyme had RNAseH activity. Choi and co-workers
[56] expressed the intact duck hepatitis B virus polymerase in yeast
and reported that it had a weak RNAse activity. Finally, Potenza
Figure 1. The HBV replication cycle. HBV replicates by reverse
transcription in the cytoplasm of infected hepatocytes. After comple-
tion of reverse transcription, intracellular capsids can either be
transported into the nucleus to maintain the cccDNA pool (Recycling),
or they can be enveloped and secreted from the cells as mature virions
(Secretion). Inhibiting RNAseH activity blocks plus-strand DNA synthesis
during reverse transcription; this would prevent both recycling and
secretion of virions. The hepatocyte is represented as a rectangle, the
nucleus as an oval, HBV capsids as a hexagon, and the viral lipid
envelop as a circle surrounding the extracellular capsids. HBV proteins
are green or black, RNAs are red, and DNAs are blue.
doi:10.1371/journal.ppat.1003125.g001
Author Summary
Current therapy for HBV blocks DNA synthesis by the viral
reverse transcriptase and can control the infection indef-
initely, but treatment rarely cures patients. More patients
could be cured by suppressing HBV replication further
using a new drug in combination with the existing ones.
The HBV RNAseH is a logical drug target because it is the
second of only two viral enzymes that are essential for viral
replication, but it has not been exploited, primarily because
it is very difficult to produce active enzyme. We expressed
active recombinant HBV RNAseHs and demonstrated that it
was suitable for antiviral drug screening. Twenty-one
candidate HBV RNAseH inhibitors were identified based
on antagonists of the HIV RNAseH and integrase enzymes.
Twelve of these compounds inhibited the HBV RNAseH in
enzymatic assays, and one inhibited HBV replication in cell-
based assays. The high percentage of compounds devel-
oped against the HIV RNAseH and integrase that were also
active against the HBV RNAseH indicates that the extensive
drug design efforts against these HIV enzymes can be used
to guide anti-HBV RNAseH drug discovery.
The HBV RNAseH as a Drug Target
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et al. [57] expressed the HBV RNAseH domain as a synthetic
gene in E. coli. Following purification from inclusion bodies and
refolding, this enzyme had RNAse activity. However, no follow-up
reports have appeared with any of these systems, possibly due to
the technical difficulties associated with the purification protocols
and/or contamination challenges with host RNAseH or other
RNAse classes.
Human Immunodeficiency Virus (HIV) reverse transcription also
requires a virally encoded RNAseH activity [58], and consequently the
RNAseH has attracted much attention as a potential drug target
[38,59–78]. Over 100 anti-HIV RNAseH compounds have been
reported, typically with inhibitory concentration-50% (IC50) values in
the low mM range. Most of the compounds inhibit HIV replication in
culture, typically with effective concentration-50% (EC50) values that
are ,10-fold higher than the biochemical IC50 values. These
compounds are often modestly cytotoxic, leading to therapeutic indices
(TI) that are usually ,10. Second-generation inhibitors with
substantially improved efficacy have been reported, but their TI values
were not necessarily improved markedly [68–70]. Despite these
limitations, compounds with efficacy and TI values appropriate for a
drug exist [68,75]. Most of the compounds inhibit the RNAseH by
binding to the enzyme and chelating the divalent cations in the active
site [64,65,69,70,73,76], but compounds that appear to inhibit the
RNAseH by altering the enzyme’s conformation or its interaction with
nucleic acids have also been reported [63,75]. As predicted from their
common membership in the nucleotidyl transferase superfamily, some
anti-HIV RNAseH compounds can inhibit the HIV integrase,
and some anti-integrase compounds can inhibit the RNAseH
[59,68,70,74,79].
The ability of the nucleos(t)ide analog drugs to profoundly
suppress HBV in most patients and to cure HBV infection in a few
patients indicates that they can push the virus to the brink of
elimination. This presents an opportunity to cure many more
patients by suppressing HBV replication further, but achieving a
cure will require novel drugs against targets other than the DNA
polymerase active site. These drugs would be used in combination
with the nucleos(t)ide analogs to suppress viral replication below
the level needed to maintain the cccDNA. A logical target would
be the second of HBV’s two enzymatic activities, the RNAseH.
Here, we report production of enzymatically active recombinant
HBV RNAseH suitable for low throughput antiviral drug
screening. Using this novel reagent, we demonstrated that the
HIV RNAseH and integrase are similar enough to the HBV
RNAseH to allow information derived from HIV RNAseH and
integrase inhibitors to guide identification of anti-HBV RNAseH
compounds.
Results
Confirmation of key HBV RNAseH active site residues
The HBV DEDD residues have been implicated to be D702,
E731, D750, and D790 (numbering for HBV strain adw2) by
sequence alignments against other RNAseHs (Fig. 2), but only
D750 has been experimentally confirmed to be essential for
RNAseH activity [48]. Therefore, we introduced D702A, E731A,
D750V, and D790A mutations into the predicted DEDD motif
residue in an HBV genomic expression vector. The wild-type and
mutant genomes were transfected into Huh7 cells, five days later
Figure 2. Alignments between the HBV RNAseH and the HIV-1 RNAseH and integrase. Manually optimized alignments between HBV
RNAseH and A. the HIV-1 RNAseH, or B. the HIV-1 integrase. The HBV genotype D sequence is from Genbank entry V01460 and the HIV-1 sequences
are from strain HXB2; Genbank K03455.1. Identical residues are shaded in black and similar residues are shaded in gray. * indicates the conserved
nucleotidly transferase superfamily active site carboxylates (D-E-D-D for the RNAseH enzymes and D-D-E for the integrase). The numbering for each
sequence is indicated at top. Residue 1 for the HBV RNAseH domain is amino acid 684 in the full-length polymerase protein (strain adw2) and residue
1 for the HIV-1 RNAseH domain is amino acid 441 of the full-length reverse transcriptase (strain HXB2).
doi:10.1371/journal.ppat.1003125.g002
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intracellular viral capsids were purified, and then HBV DNAs
within the particles were detected by Southern analysis. All four
mutants supported DNA synthesis and hence could be analyzed by
this approach. The signature of an RNAseH-deficient enzyme is
production of RNA:DNA heteroduplexes that migrate like double-
stranded DNAs on native gels but as faster-migrating single-
stranded DNAs of multiple lengths following digestion of the
capsid-derived nucleic acids with exogenous RNAseH. DNAs
produced by the wild-type genome were unaffected by treatment
with RNAseH prior to electrophoresis (Fig. 3). Mutating each of
the four predicted RNAseH DEDD residues blocked production
of the slowest-migrating double stranded forms (mature relaxed-
circular DNAs) and led to accumulation of smaller forms that
migrated similar to the less-mature relaxed-circular DNAs
produced by the wild-type genome. Treatment of the nucleic
acids from the mutant genomes with exogenous RNAseH
collapsed the double-stranded forms to single-stranded forms
(Fig. 3). Therefore, all four mutants were RNAseH deficient.
Production of enzymatically active recombinant HBV
RNAseH
We expressed HBV RNAseH sequences from the HBV isolate
employed by Potenza et al. [57] in E. coli as a carboxy-terminally
hexahistidine tagged recombinant protein, but we moved the
amino terminus nine residues upstream to residue 684 of the HBV
polymerase because we felt this site was more probable to yield
soluble protein (HRHPL; Fig. 4A). As a negative control, we
mutated two of the DEDD active site residues (D702A and
E731A). These constructs were expressed in E. coli, soluble lysates
were prepared, and the lysates were subjected to nickel-affinity
chromatography.
Five proteins of approximately 80, 70, 26, 14, and 11 kDa
detectable by Coomassie staining were recovered following
chromatography, none of which correlated with the predicted
mass of 18.9 kDa for HRHPL (Fig. 4B). Mass spectrometry
identified the dominant 26 kDa band as the E. coli prolyl isomerase
SlyD. Concentrating the samples seven-fold did not increase the
RNAseH to levels detectable by Coomassie staining. Western
analysis with anti-polyhistidine antibodies revealed a large number
of cellular bands but failed to unambiguously identify HRHPL.
This was presumably due to the presence of histidine-rich regions
in the bacterial proteins that promoted their binding to the nickel-
affinity resin (e.g., SlyD). However, western analysis with the anti-
HBV RNAseH domain antibody 9F9 ([80]; Santa Cruz Biotech-
nology) revealed a small amount of recombinant HBV RNAseH
that migrated close to its predicted mass plus a larger amount of
the protein that migrated as a doublet near 15 kDa (Fig. 4B). The
doublet is presumably due to proteolysis near the protein’s N-
terminus because the antibody epitope and hexahistidine tag are at
the C-terminus. The sizes of the truncation products imply that
they were cleaved near HRHPL residue 36, which would remove
the essential D702 carboxylate (HRHPL residue 20) and inactivate
the protein. These experiments indicate we could express and
enrich small but detectable amounts of soluble recombinant HBV
RNAseH.
We tested activity of the recombinant HBV RNAseHs in a
DNA oligonucleotide-directed RNA cleavage assay. In this assay,
a DNA oligonucleotide is annealed to a uniformly-labeled RNA to
create an RNA:DNA heteroduplex. Cleavage of the RNA in the
heteroduplex yields two RNA fragments of predictable size that
are resolved by electrophoresis and detected by autoradiography
(Fig. 5A). We employed the 264 nt RNA (DRF+) used in our
previous RNAseH assays [46] in combination with two DNA
oligonucleotide pairs. One oligonucleotide in each pair was the
correct polarity to anneal to the DRF+ RNA and the other was its
inverse complement as a negative control.
Oligonucleotide-directed RNAseH assays were conducted with
wild-type HRHPL enzyme and the RNAseH-deficient D702A
mutant. The RNA was not cleaved when the non-complementary
oligonucleotides were employed in the reactions (Fig. 5B),
demonstrating that the enzyme preparations did not contain
non-specific RNAse activity. Use of complementary oligonucleo-
tide #1 (D25072) led to complete cleavage of the DRF+ RNA by
E. coli RNAseH into products of 154 and 94 nt, and to partial
cleavage of the RNA at the same site by wild-type HRHPL
(Fig. 5B). The large majority of this RNAseH activity was due to
the HBV enzyme because mutating DEDD residues D702A and/
or E731A sharply reduced cleavage of the RNA. Note that
although the relative yield of full-length mutant RNAseH was less
than the wild-type enzyme in Fig. 4, in other preparations the
amount of mutant RNAseH exceeded the amount of wild-type
enzyme (e.g., Fig. 6). In all cases, the enzymatic activity associated
with the mutant RNAseH preparations was far lower than in the
Figure 3. Identification of the DEDD motif in the HBV RNAseH
active site. Wild-type and mutant HBV genotype A genomic
expression vectors were transfected into cells, intracellular capsids
were isolated five days later, and viral nucleic acids were purified from
the capsids. The nucleic acids were divided into two aliquots; one
aliquot was treated with DNAse-free E. coli RNAseH to destroy RNA:DNA
heteroduplexes and the other was mock treated. The nucleic acids were
resolved by agarose electrophoresis and HBV DNAs were detected by
Southern analysis. The signature of an RNAseH-deficient genome is
production of RNA:DNA heteroduplexes in which the DNA migrates as
double-stranded species without treatment with exogenous RNAseH
treatment but as singe-stranded species following degradation of the
RNA. The positions of the duplex linear (DL) and full-length single-
stranded linear (SL) HBV DNA markers are shown. DS indicates the
spectrum of double-stranded nucleic acids produced by reverse
transcription, and SS indicates the spectrum of single-stranded nucleic
acids.
doi:10.1371/journal.ppat.1003125.g003
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wild-type preparations. The residual cleavage products in reac-
tions with the mutant enzymes appear to be non-specific
breakdown products from the RNA substrate and/or digestion
products from trace contamination with bacterial RNAseH. The
RNA products shifted sizes as expected when complementary
oligonucleotide #2 (D2543M-Sal, which anneals 33 nt closer to
the 39 end of the RNA) was employed in the RNAseH assays
(Fig. 5B): the larger fragment became larger (187 nt) and the
smaller fragment became smaller (61 nt). These data demonstrate
that the RNAse activity in HRHP is specific for RNA annealed to
the DNA oligonucleotides, and hence confirm that it is an
RNAseH activity.
Finally, we synthesized a quenched fluorescent RNA:DNA
chimeric hairpin oligonucleotide substrate (RHF1) to confirm
RNAseH activity with a different assay. RHF1 has fluorescein at
its 59 end, 20 nt of RNA, a 4 nt DNA hairpin, 20 nt of DNA
complementary to the RNA, and an Iowa Black FQ quencher at
the 39 terminus. The hairpin brings the fluorescein and quencher
into close proximity, and digesting the RNA frees the fluorescein
and increases its fluorescence (Fig. 5C). RHF1 was terminally
digested with E. coli RNAseH, the reactions were terminated with
10 mM EDTA, and fluorescence was measured. This digestion
amplified the fluorescence of RHF1 22-fold, indicating a 95%
quenching efficiency. RHF1 was then employed in an RNAseH
assay with buffer alone, wild type HBV RNAseH (HRHPL), and
HRHPL-D702A/E731A. RNAseH activity for HRHPL was
about 2-fold higher than the no-enzyme control, and mutating
the RNAseH active site eliminated this activity (Fig. 5D). This
weak signal (7% of the maximal signal in this assay) appears to be
due to poor binding between the small substrate and the RNAseH
in the relatively high ionic strength of the reactions because
detection of RNAseH activity required reducing the NaCl
concentration from 190 to 130 mM.
These data indicate that we can readily detect HBV RNAseH
activity in the enriched bacterial extracts despite the fact that the
HBV RNAseH is a minor component of the mixture.
Optimization of reaction conditions
The optimal enzymatic conditions for the HRHPL HBV
RNAseH were determined by systematically varying the reaction
components in the oligonucleotide-directed RNAseH assay
(Table 1). Recombinant HBV RNAseH was active over a wide
range of pH values but was most active near 8.0. Its activity
maximum was at 190 mM NaCl and it became able to digest
single-stranded RNA below ,100 mM NaCl. The RNAseH
required ,5 mM Mg++ for maximal activity; increasing Mg++
beyond ,7 mM suppressed RNAseH activity, and inclusion of
Mn++ in the reactions led to nonspecific degradation of single-
stranded RNA. The enzyme became inactive at low reductant
concentrations, but it could tolerate up to 2% DMSO. It was
stable upon storage in liquid nitrogen, and only marginal loss of
activity was observed following five sequential freeze-thaw cycles.
Recombinant RNAseH enzymes from other HBV
genotypes
HBV has eight genotypes (A–H, plus provisional identification
of genotypes I and J) that differ by.8% at the sequence level [81].
We cloned HBV RNAseH domains for genotype A, B, C, and H
Figure 4. Recombinant HBV RNAseH proteins. A. Structure of the recombinant RNAseHs. The HBV polymerase with its major domains labeled is
at top. The recombinant RNAseH derivatives are shown below with the C-terminal hexahistidine tag in brown. TP, terminal protein domain; RT,
reverse transcriptase domain; *, mutations D702A or E731A to RNAseH active site residues. B. Proteins in the enriched lysates. The left panel is a
Coomassie-blue stained SDS-PAGE gel of enriched RNAseH extracts as employed in the RNAseH assays. The right panel is a western blot of the
extracts employing monoclonal antibody 9F9 which recognizes an epitope near the C-terminus of the HBV polymerase.
doi:10.1371/journal.ppat.1003125.g004
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isolates using the same structure as the HRHPL construct
(genotype D) to determine whether HBV’s genetic diversity leads
to variable sensitivity to inhibitors that must be taken into account
during drug development (Fig. 6A). The protein profile detectable
by Coomassie staining following expression and nickel-affinity
enrichment for all additional constructs was the same as for
HRHPL. Western blotting with antibody 9F9 detected the
genotype B, C, and D RNAseHs, with the genotype C enzyme
appearing primarily as the full-length protein (Fig. 6B). The failure
to detect the genotype A and H RNAseHs was due either to lack of
accumulation of the proteins or to amino acid variations in the C-
terminus of the protein where the antibody epitope is located [80].
The genotype A, B, C, D, and H RNAseH extracts were
assessed with the oligonucleotide-directed RNAseH assay (Fig. 6C).
The genotype A and B enzymes were inactive, activity of the
genotype C RNAseH ranged from undetectable to modest in
replicate experiments, and activity of the genotype H enzyme was
similar to that of the genotype D RNAseH. The [NaCl]-, [Mg++]-,
temperature-, and pH-profiles of the genotype H RNAseH were
very similar to those of the genotype D enzyme (data not shown).
Therefore, we can express recombinant HBV genotype B, C, D,
and H RNAseH proteins that are detectable by enzymatic assays
and/or western blotting, but only the genotype D and H proteins
are consistently active.
Identification of anti-HBV RNAseH compounds
We hypothesized that the HBV RNAseH may be inhibited by
antagonists of the HIV RNAseH based on the similarity of the
reactions they catalyze. We identified 10 compounds known to
inhibit the HIV RNAseH or that were predicted by chemical
structure-activity relationships to do so (Table 2 and Supplementary
Fig. S1). We further hypothesized that anti-HIV integrase
compounds may inhibit the HBV RNAseH because the integrase
and RNAseH are both members of the nucleotidyl transferase
superfamily and because some anti-HIV RNAseH and integrase
compounds can cross-inhibit their target enzymes [59,68,70,74,79].
Consequently, we also obtained 11 compounds either known to
inhibit the HIV integrase or predicted to do so by chemical
structure-activity relationships (Table 2 and Supplementary Fig.
S1). We first measured the effect of irrelevant compounds
(tryptophan, sucrose, and IPTG) on the RNAseH assay. These
compounds reduced RNAseH activity of HRHPL to 5269%
relative to the DMSO vehicle control (Figs. 7 and 8A). This allowed
us to define the mean of the residual activity in the presence of the
irrelevant compounds minus two standard deviations of the
irrelevant controls as a threshold reduction of the RNAseH activity
that must be exceeded before we considered inhibition by the test
compounds to be relevant. Using this threshold, 12 of the 21
compounds inhibited the HBV genotype D RNAseH at 10 mM
(Fig. 7, Table 2, and Supplementary Table S1). These 21
compounds were also screened against the HBV genotype H
RNAseH using the oligonucleotide-directed RNAseH assay.
The unexpectedly high frequency of inhibition of the genotype D
enzyme led us to question the mechanism(s) by which it was inhibited
by the compounds. We addressed this in two manners. First,
RNAseH inhibitors usually block the HIV enzyme by interfering with
Figure 5. Recombinant HBV RNAseH is enzymatically active. A. Oligonucleotide-directed RNAseH assay. Uniformly 32P-labeled RNA (blue or
red) is annealed to a complementary DNA oligonucleotide (black). RNAseH activity cleaves the RNA in the heteroduplex formed where the
oligonucleotide anneals to the RNA and yields two products (P1 and P2). B. Recombinant HBV RNAseH is active. An oligonucleotide-directed RNAseH
assay was conducted with E. coli RNAseH, wild-type HBV RNAseH (HRHPL), or RNAseH-deficient HRHPL (D702A). A complementary oligonucleotide (+)
or non-complementary oligonucleotide (2) was mixed with labeled DRF+ RNA and the reactions were incubated to allow RNAseH activity. The
products were resolved by SDS-PAGE and the RNAs were detected by autoradiography. Oligonucleotide set 1 was D25072 and D2526+ and
oligonucleotide set #2 was D2543M-Sal and D2453+. The positions of the cleavage products (P1 and P2) are indicated in blue for reactions
containing oligonucleotide D25072 and in red for reactions containing oligonucleotide D2543M-Sal. C. FRET-based RNAseH assay. A self-
complementary chimeric RNA:DNA synthetic oligonucleotide (RHF1) forms a stem-loop in which the stem is an RNA:DNA heteroduplex. The stem
brings the fluorescein (F) and quencher (Q) at the 59 and 39 ends of the oligonucleotide into close proximity. Cleavage of the RNA releases the
fluorescein and increases its fluorescence. D. Detection of HBV RNAseH activity employing the fluorescent assay. The substrate in panel C was
employed in an RNAseH assay employing buffer alone, wild-type HBV RNAseH (HRHPL), or RNAseH-deficient HRHPL (D702A/E731A). *, P,0.05.
doi:10.1371/journal.ppat.1003125.g005
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the divalent cations in the active site [64,65,69,70,73,76]. Conse-
quently, we asked whether the compounds act non-specifically by
chelating Mg++. Isothermal calorimetry demonstrated that com-
pounds#5, 6, and 8 did not bind Mg++ in the absence of the protein
extracts (data not shown). This is consistent with their inability to
significantly inhibit poly-G synthesis by the Hepatitis C virus (HCV)
RNA polymerase which is also active in 5 mM Mg++ [82] (Fig. 8B).
Second, we titrated selected compounds from 50 to 0.5 mM to
examine dose-responsiveness of inhibition (Fig. 8C). Compound#12
had a typical inhibition curve with an IC50 of 2.5 mM in this
experiment; similar smooth dose-response curves were observed for
compounds #39 and 40 (data not shown). In contrast, inhibition by
compound#6 plateaued at 20–30% between 3 and 40 mM but then
increased to 75% at 50 mM. Compound #8 was ineffective below
5 mM, it inhibited the enzyme by 40–85% between 10 and 30 mM,
and caused aberrant migration of the RNA at 40 and 50 mM. These
data indicate that some compounds behaved as predicted from their
mechanism of action against HIV, but that inhibition by other
compounds may have been due to alternative effects, possibly
including interaction with the RNA and/or aggregation of the
enzyme.
Figure 6. Recombinant RNAseHs from HBV genotypes A, B, C, D, and H. A. Sequence alignment for genotype A, B, C, D, and H versions of
the HBV RNAseH expression construct HRHPL. The additional methionine at residue 10 of the genotype D sequence is a product of the cloning
strategy; this insertion has no impact on the RNAseH activity because the first 9 amino acids of HRHPL can be deleted without altering the
biochemical profile of the enzyme. * indicates the DEDD active site residues, and the hexahistidine tag at the C-terminus is underlined. Residue 1 for
the HBV RNAseH domain is amino acid 684 in the full-length polymerase protein (strain adw2). B. Western analysis of RNAseH proteins in the
enriched lysates probed with the anti-HBV RNAseH monoclonal antibody 9F9. C. RNAseH activity of RNAseH from HBV genotypes A, B, C, D, and H
detected by the oligonucleotide-directed RNA cleavage assay. HRHPL-D702A (genotype D) is a negative control. gt, genotype.
doi:10.1371/journal.ppat.1003125.g006
Table 1. Optimal reaction conditions.
Tris pH 7.5 65 mM
NaCl 190 mM
MgCl2 5 mM
DTT 5 mM
Glycerol 6%
DMSO 1%
NP40 0.05%
DNA Oligo (20 mer) 0.15 mg/ml
RNA (264 nt) 0.025 mg/ml
Temperature 42uC
RNAseIn 0.5 U/ml
doi:10.1371/journal.ppat.1003125.t001
The HBV RNAseH as a Drug Target
PLOS Pathogens | www.plospathogens.org 7 January 2013 | Volume 9 | Issue 1 | e1003125
Figure 7. Inhibition of the HBV RNAseH by candidate compounds selected for their similarity to antagonists of the HIV RNAseH and
integrase. Candidate inhibitors (compounds #2-40) and irrelevant compounds (tryptophan, sucrose, and IPTG) were included at 10 mM in a
standard oligonucleotide-directed RNAseH assay employing wild-type genotype D HBV RNAseH (HRHPL). DMSO, vehicle control. Error bars are6 one
standard deviation from three to seven replicates. The dashed red line indicates the mean residual activity in the irrelevant control reactions (52%)
and the solid red line is two standard deviations of the irrelevant control assays below their mean (33%). Compounds that inhibited the RNAseH to
33% or below were considered to be positive (‘‘+’’ in Table 2). *, P,0.05 by T-test against the pooled data for the irrelevant controls; **, P,0.01.
doi:10.1371/journal.ppat.1003125.g007
Table 2. Candidate RNAseH inhibitors and data summary.
Compound RNAseH assays2 HBV Replication3
Number Name1 HIV template gtD gtH gtA gtD
2 Sigma 74540 RNAseH 2 2 2 2
3 Sigma n8164 RNAseH 2 2 2
4 TimTec ST029023 RNAseH +/2 2 2 2
5 Enamine T0506-3483 RNAseH +/2 2 2 2
6 Chembridge 7929959 RNAseH +/2 2 2 2
7 Idofine 02030 Integrase 2 2 2
8 Sigma S439274 Integrase + 2 2 2
9 Sigma 70050 Integrase + 2 2
10 Selleck S2001 Integrase + 2 2
11 Selleck S2005 Integrase + 2 2
12 Napthyridinone4 RNAseH + ++ + +
13 DHBNH4 RNAseH 2 +/2 2
14 THBNH4 RNAseH 2 + +/2 2
15 BHMP074 RNAseH 2 +/2 2
30 Chembridge 7248520 Integrase ++ +/2 2
31 Chembridge 5104346 Integrase + 2 2
34 Indofine D-009 Integrase + + 2
35 TCI America D1118 Integrase + +/2 2
38 Vistas M Lab STK317995 RNAseH ++ +/2 2
39 Asinex BAS0223612 Integrase ++ + 2
40 NIH 118-D-24 Integrase ++ ++ +/2 2
1Structures are in Supplemental Fig. S1.
2Inhibitory activity in the biochemical RNAseH assay at 10 mM; quantitative data are in Supplemental Table S1. Cutoff values were established relative to the mean and
standard deviation of RNAseH activity in the presence of the irrelevant compounds tryptophan, sucrose, and IPTG normalized to the vehicle control. 2, Residual activity
greater than one standard deviation below the mean irrelevant inhibition ($43% activity); +/2, Residual activity between one and two standard deviations below the
mean irrelevant inhibition (42–34% activity); +, residual activity between two and three standard deviations below the mean irrelevant inhibition (33–25% activity); ++,
residual activity less than three standard deviations below the mean irrelevant inhibition (#24% activity).
3Inhibitory activity against HBV replication in Huh7 cells at 10 mM. +, clear inhibition; 2, no detectable inhibition; +/2, inhibition observed in some but not most assays.
4Napthyridinone [68]; DHBNH, dihydroxy benzoyl naphthyl hydrazone [75,78]; THBNH, trihydroxy benzoyl naphthyl hydrazone [106]; BHMP07 [78].
doi:10.1371/journal.ppat.1003125.t002
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Activity of HBV RNAseH inhibitors against human
RNAseH1
A likely cause of cellular toxicity for anti-HBV RNAseH
drugs would be inhibition of human RNAseH1 because it is
responsible for about 80% of the RNAseH activity in human
cells [83,84]. Therefore, we cloned the human RNAseH1 with
an N-terminal hexahistidine tag, expressed it in E. coli, and
enriched the protein by nickel affinity chromatography. The
same spectrum of contaminating E. coli proteins as was
observed for the other RNAseH preparations was detectable
by Coomassie staining, but RNAseH1 could be detected at its
predicted mass of 32 kDa (Fig. 9A). This enzyme was active in
the oligonucleotide-directed and fluorescent RNAseH assays
(Fig. 9B and data not shown). To determine how inhibition of
human RNAseH1 compared to inhibition of the HBV
RNAseH, we titrated RNAaseH1 to yield similar levels of
activity as the HBV enzyme, and then we directly compared
the ability of compounds #8-12 to inhibit human RNAseH1
and HRHPL at 10 mM. All five compounds inhibited the HBV
RNAseH. Compound #8 inhibited RNAseH1 well, #9 and 12
inhibited it weakly, and #10 and 11 had no effect on
RNAseH1. Therefore, it is possible to inhibit the HBV
RNAseH without inhibiting human RNAseH1.
Anti-HBV RNAseH compounds can inhibit HBV
replication in culture
Finally, we asked whether HBV RNAseH inhibitors could block
HBV replication in culture. Huh7 cells were transfected with
genomic expression vectors for HBV genotype A or D isolates, the
cells were treated with 10 or 50 mM compounds, and viral nucleic
acids were isolated from intracellular HBV capsids after four days.
Replicate nucleic acid aliquots were mock treated or treated with
DNAse-free E. coli RNAseH to destroy RNA:DNA heteroduplex-
es, and then HBV DNAs were detected by Southern blotting. The
signature of RNAseH inhibition is accumulation of RNA:DNA
heteroduplexes that migrate as double-stranded species without
exogenous RNAseH treatment but as faster-migrating single-
stranded DNAs following RNAseH treatment.
The mobility of the DNAs synthesized in cells containing the
wild-type genotype A genome was unaffected by exogenous
RNAseH treatment (Fig. 10). Ablation of RNAseH activity by the
D702A mutant altered migration of the double-stranded forms,
and treatment of these samples with RNAseH collapsed the
double-stranded forms to single-stranded DNAs (Fig. 10 left
panel). The mobility of HBV DNAs from cells replicating HBV
genotype A treated with DMSO was unaffected by RNAseH
digestion (Fig. 10 center panel), but treatment of cells with
Figure 8. Specificity of anti-HBV RNAseH compounds. A. Inhibition of HBV genotype D RNAseH by irrelevant compounds at 10 mM in the
oligonucleotide-directed RNAseH assay. Compound #4 was employed as an example HBV RNAseH inhibitor. B. Anti-HBV RNAseH inhibitors do not
significantly inhibit the HCV RNA polymerase. The ability of compounds #5, 6 and 8 to inhibit production of poly-G by the HCV RNA-directed RNA
polymerase was measured in a primed homopolymeric RNA synthesis assay [82]. The compounds were employed at 10 mM. DMSO, vehicle control. C.
Dose-responsiveness of HBV RNAseH inhibition. The effects of compounds #6, 8, and 12 on the RNAseH activity of HRHPL (genotype D) were
measured at concentrations ranging from 0.5 to 50 mM. The dose-response profile is plotted for compound #12.
doi:10.1371/journal.ppat.1003125.g008
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compound #12 at 10 mM blocked production of the slowest-
migrating double-stranded forms and led to accumulation of
RNA:DNA heteroduplexes whose mobility increased upon
removal of RNA. Treatment of cells with 3 to 50 mM compound
#12 revealed that the degree of inhibition was proportional to the
concentration of the compound (data not shown). Plus-strand
preferential real-time PCR across the gap in the minus-polarity
viral DNA revealed that 10 mM compound #12 reduced plus-
strand DNA accumulation to 7.3% of the DMSO-treated control
(data not shown). None of the other compounds reproducibly
inhibited HBV genome synthesis (Table 2), but compound #14
(25 mM) inhibited HBV replication in one experiment and #40
(50 mM) inhibited replication in another experiment. Overt
cellular toxicity was not observed for any of the compounds at
10 mM. Toxicity was often observed at higher concentrations; this
led to the reduced yield of HBV DNA from cultures treated with
50 mM compounds #5, 6, and 8 in Fig. 10.
The effect of the compounds on replication of a genotype D
isolate was tested to evaluate the generality of the results with the
genotype A isolate. Treatment of capsid-derived nucleic acids from
the DMSO control cells with exogenous RNAseH led to partial
conversion of the double-stranded molecules to single-stranded
forms. Therefore, RNA:DNA heteroduplexes accumulated in
capsids even in the absence of RNAseH inhibitors. This indicates
that the RNAseH activity during reverse transcription was
incomplete for this isolate. Very few of the most slowly-migrating
double-stranded nucleic acids accumulated in cells treated with
10 mM compound #12, and many of the duplex DNAs collapsed
to single-stranded forms upon treatment with exogenous RNAseH.
Therefore, the inefficient HBV RNAseH in this isolate created a
high background, but we were able to detect suppression of the
HBV RNAseH activity above background by compound #12.
None of the other compounds tested against the genotype D
isolate detectably inhibited HBV replication (Table 2).
Therefore, compound #12 inhibited replication of HBV
genotypes A and D in cells at low mM concentrations by blocking
RNAseH activity, with the anti-RNAseH effect being somewhat
less pronounced than complete ablation of the activity by mutating
the RNAseH active site.
Discussion
Nucleos(t)ide analog therapy has turned chronic HBV infection
into a disease that can be controlled indefinitely, with enormous
benefits to patients [6,7,85]. However, the infection is very rarely
cleared, so treatment is essentially life-long, very expensive, and
may be associated with unpredictable long-term side effects.
Despite these limitations, the ability of protracted nucleos(t)ide
analog therapy to slowly suppress cccDNA and HBsAg and to cure
a small minority of HBV patients [10–13,21–23] indicates that the
nucleos(t)ide analogs can push the virus to the brink of elimination.
This implies that many more patients could be cured by
employing a new drug against a novel HBV target in combination
with the nucleos(t)ide analogs to further suppress HBV replication.
Here, we report production of recombinant HBV RNAseH
suitable for low throughput antiviral drug screening and demon-
strate that chemical structure-activity relationships based on HIV
RNAseH and integrase inhibitors can guide identification of
compounds likely to inhibit the HBV enzyme.
Production of soluble recombinant HBV polymerase or
domains of the polymerase is notoriously difficult, and our
experience with the HBV RNAseH domain was no exception.
Soluble HBV RNAseH accumulated to low levels in E. coli and
was a minor component of the extracts even after nickel-affinity
enrichment (Fig. 4). Much of the RNAseH was apparently cleaved
near its N-terminus, and these cleavage products are unlikely to be
active because their sizes imply that they lack D702. Although the
concentration of the intact enzyme was very low, its specific
activity was high enough to yield readily detectable signals in both
radioactive and fluorescent RNAseH assays (Fig. 5). Potenza et al.
[57] previously expressed recombinant HBV RNAseH that was
very similar to HRHPL (genotype D), but their expression
conditions led to accumulation of the enzyme in inclusion bodies,
necessitating refolding following purification under denaturing
conditions. The refolded enzyme possessed RNAse activity, but
this activity was not demonstrated to be an RNAseH. Differences
between the assays employed here and in Potenza’s study prevent
comparison of the specificity and specific activity of the enzyme
prepared under native and denaturing conditions.
The optimal reaction conditions for the recombinant HBV
RNAseH (Table 1) were typical for nucleic-acid modifying
enzymes and were similar to conditions in which recombinant
hepadnaviral reverse transcriptase is active [86–88]. Its activity
was dependent upon a divalent cation, but it became active against
Figure 9. Activity of HBV RNAseH inhibitors against human
RNAseH1. A. Proteins in the enriched recombinant human RNAseH1
lysates employed in the RNAseH reactions were detected by
Coomassie-blue staining following SDS-PAGE. B. An oligonucleotide-
directed RNAseH assay was conducted with wild-type HBV RNAseH
(genotype D) and recombinant human RNAseH1 under identical
reaction conditions. The inhibitory compounds were employed at
10 mM. The upper and lower panels are from the same experiment and
the data were collected on a single sheet of film, so the reactions can be
directly compared. DMSO, vehicle control. S, the DRF+ substrate; P1 and
P2, RNAseH cleavage products.
doi:10.1371/journal.ppat.1003125.g009
The HBV RNAseH as a Drug Target
PLOS Pathogens | www.plospathogens.org 10 January 2013 | Volume 9 | Issue 1 | e1003125
single-stranded RNA in addition to RNA in a heteroduplex when
Mn++ was substituted for Mg++ (data not shown). This is similar to
the reduced fidelity of nucleic acid polymerases (including the duck
HBV polymerase) in the presence of Mn++ [89–91]. The RNAseH
had a relatively high NaCl optimum of 190 mM and it lost
specificity for heteroduplex RNA at low ionic strength (data not
shown). Importantly given that a primary goal of this study was to
produce enzyme suitable for antiviral drug screening, recombinant
HBV RNAseH was stable upon storage in liquid nitrogen, could
be repeatedly frozen and thawed, and was fully active in up to 2%
DMSO. Therefore, enzyme suitable for low-throughput anti-HBV
RNAseH drug screening has been produced.
The HIV RNAseH is a very active target of ongoing
antiviral drug discovery [38,59–78], but to our knowledge
none of the anti-HIV RNAseH compounds have entered
clinical trials yet. This is primarily due to the relatively low
therapeutic indexes of most known anti-HIV RNAseH
compounds. Similar challenges were faced by the HIV
integrase field in the early stages of development of anti-
integrase drugs. Many inhibitors were discovered, but clinical
development did not begin until strand transfer inhibitors,
active site metal binders, etc. were discovered. The failure to
advance to HIV RNAseH inhibitors to clinical trials may also
be partially due to the large number, high potency, and diverse
profile of existing anti-HIV drugs. In contrast, current anti-
HBV therapies are primarily based on a single class of
inhibitors, nucleos(t)ide analogs. Hence, inhibitors of a new
HBV enzymatic function would address the current challenges
of limited efficacy and cross-resistance among the nucleos(t)ide
analogs, and this would allow meaningful combination
therapies for HBV similar to HAART that dramatically
changed the landscape of anti-HIV therapy.
The ability to template HBV RNAseH drug discovery on the
HIV experience would greatly accelerate anti-HBV efforts. The
HIV data could narrow the chemical space to be assessed during
screening, compounds synthesized during anti-HIV RNAseH
screening would be available for immediate screening against
HBV, and the toxicity profile of some of these compounds is
known. Templating anti-HBV RNAseH drug development on
HIV efforts would be analogous to the development of the anti-
HBV nucleos(t)ide analogs, which was greatly facilitated by the
parallel development of anti-HIV nucleoside analogs [92].
Twenty-one candidate RNAseH inhibitors were selected due to
their similarity to known inhibitors of the HIV RNAseH or
integrase. Twelve of these compounds (57%) inhibited the HBV
RNAseH at 10 mM to below the threshold defined by control
reactions with irrelevant compounds (Fig. 7 and Table 2).
Importantly, 10 of 11 compounds analogous to anti-HIV integrase
compounds inhibited the HBV RNAseH, including both approved
anti-HIV integrase drugs, raltegravir (compound #11) and
elvitegravir (#10). This is consistent with the membership of both
the RNAseH and integrase in the nucleotidyl transferase
superfamily of enzymes. Therefore, there is enough similarity
between the HBV RNAseH and the HIV RNAseH and integrase
active sites to guide screening for anti-HBV RNAseH compounds.
Most anti-HIV RNAseH inhibitors bind to the enzyme and
chelate the divalent cations in the active site [64,65,69,70,73,76].
Similarly, anti-HIV integrase compounds that target the active site
typically do so by binding to the enzyme or the enzyme plus DNA
and chelating the active site divalent cations [93]. The compounds
tested here were selected for the ability to bind to Mg++ ions
oriented as they are in the HIV RNAseH or integrase active sites,
and hence inhibition of the HBV enzyme is predicted to be
through binding to the active site and interfering with the Mg++
Figure 10. Inhibition of HBV replication in culture by RNAseH inhibitors. Genotype A or D HBV genomic expression vectors were
transfected into cells, intracellular capsids were isolated four days later, and viral nucleic acids were purified from the capsids. The nucleic acids were
divided into two aliquots; one aliquot was treated with DNAse-free E. coli RNAseH to destroy RNA:DNA heteroduplexes and the other was mock
treated. The nucleic acids were resolved by agarose electrophoresis and HBV DNAs were detected by Southern analysis. Inhibition of RNAseH activity
leads to accumulation of RNA:DNA heteroduplexes in which the DNA migrates as double-stranded species in the mock-treated sample but as faster-
migrating singe-stranded species following RNAseH treatment. The left panel is a control in which wild-type and RNAseH-deficient D702A HBV
genomes were compared. The right two panels employed wild-type HBV in the presence of the test compounds. Compounds were employed at 10
or 50 mM as indicated. DMSO, vehicle control. The positions of the duplex linear (DL) and full-length single-stranded linear (SL) HBV DNA markers are
shown. DS indicates the spectrum of double-stranded nucleic acids produced by reverse transcription, and SS indicates the spectrum of single-
stranded nucleic acids.
doi:10.1371/journal.ppat.1003125.g010
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ions. The mechanisms by which the HBV RNAseH inhibitors
function have not been determined, but IC50 curves reveal at least
two patterns. The profiles for compounds #12, 39, and 40 were
consistent with the predicted competitive inhibition mechanism
(Fig. 8C and data not shown). In these cases, inhibition appears to
be specific. Other compounds, such as #6 and #8, had inhibition
profiles with one or more broad plateaus that were inconsistent
with simple competitive binding to the active site. In addition, the
electrophoretic mobility of the RNA was retarded at high
concentrations of compound #8 (Fig. 8C), implying that this
compound may react with the RNA substrate.
The compounds employed here were selected by structure-
activity relationships with the goal of testing whether these
relationships could predict biochemical inhibition of the HBV
RNAseH. The compounds were not selected to have other
properties necessary for a drug, such as the ability to enter cells.
Nevertheless, compound #12 inhibited HBV replication in cell
culture at 10 mM without extensive cellular toxicity (Fig. 10). The
reduction in mobility following treatment of capsid-derived nucleic
acids with E. coli RNAseH demonstrates that RNA:DNA
heteroduplexes accumulated in the viral capsid in the presence
of compound #12, confirming that these compounds blocked
HBV RNAseH activity in culture. Therefore, it is possible to
pharmacologically inhibit the HBV RNAseH in cells, and
identification of anti-HBV compounds that are active in cells
can be achieved employing structure-activity relationships based
on anti-HIV compounds. Furthermore, the ability of compounds
identified by screening against recombinant genotype D and H
enzymes to inhibit both genotype A and D isolates in culture
demonstrates that it is possible to identify RNAseH inhibitors that
are active against a range of HBV isolates.
The sensitivity profile of the HBV genotype D and H RNAseHs
to the inhibitors was not the same (Table 2). This has two
implications. First, the genotype H RNAseH may be a better
candidate for primary drug screening than the genotype D enzyme
because its inhibition profile more accurately predicted inhibition
of HBV replication in culture. Second, the variable sensitivity of
the genotype D and H enzymes to the compounds indicates that
HBV’s high genetic diversity is likely to be an important issue
during development of anti-HBV RNAseH drugs.
The key HBV molecule that must be eradicated to cure patients
is the viral cccDNA (Fig. 1) [25]. Ideally, clearing the cccDNA
would be achieved by simultaneously suppressing its synthesis rate
with the existing nucleos(t)ide inhibitors and increasing its
degradation rate with a new drug. The problem with this
approach is that we do not know how to safely destabilize the
cccDNA, so the approach that has the most realistic chance of
clearing HBV in the foreseeable future is to further suppress its
synthesis rate. Importantly, pharmacological suppression of viral
genomic synthesis may not need to completely eradicate the
cccDNA by itself because the latter stages of viral clearance may
be assisted by the immune system. HBV’s proteins, including
HBsAg [94–99], HBeAg [100,101], and the polymerase [102–
104], have immunosuppressive activities. Consequently, if viral
genomic replication can be suppressed far enough to inhibit
cccDNA synthesis rather than just virion secretion (Fig. 1) as is
usually achieved with the nucleos(t)ide analogs, levels of the
cccDNA would drop. This reduction in the transcriptional
template would reduce production of HBV’s proteins, presumably
weakening HBV’s immunosuppression and promoting immune-
mediated viral clearance.
Three challenges remain prior to beginning full-scale antiviral
drug screening against the HBV RNAseH. First, the majority of
HBV’s disease burden is caused by genotypes B and C, and we
have been unsuccessful to date in generating consistently active
recombinant RNAseH from these genotypes. This challenge is
likely to be surmountable because only a few isolates of these
genotypes have been tested for activity and because compound
#12 identified by screening against genotypes D and H inhibited
replication of HBV genotype A in culture, confirming that cross-
genotype inhibition is possible. Second, the existing tissue culture
and biochemical assays are sufficient for low throughput drug
screening, but anti-HBV RNAseH drug development is anticipat-
ed to require screening many thousands of compounds even when
the chemical search space is constrained by prior studies with
HIV. Therefore, full-scale drug screening and subsequent
mechanistic assessment of hit compounds will require improving
the yield and purity of the biochemical RNAseH assay. This
challenge should be met by further optimizing the induction and
extraction conditions, expanding the bacterial induction cultures
beyond the 100 ml scale used in this study, adding a second
purification step such as ion-exchange chromatography, and
expanding efforts to control proteolysis of the enzyme. We are
optimistic this goal can be achieved because recent improvements
to the induction and extraction conditions have increased the
specific activity of the enzyme approximately four-fold, and initial
scale-up experiments have not met with difficulty. Finally, the
HBV RNAseH assay must be adapted to a format suitable for high
throughput screening. This challenge should also be surmountable
because fluorescent RNAseH assays have been widely employed to
screen for anti-HIV RNAseH inhibitors and because the
signal:background ratio for the first-generation HBV RNAseH
fluorescent assay in Fig. 5 should be improved by increasing the
concentration of the RNAseH and/or by optimizing the substrate
structure.
Materials and Methods
Plasmids and viral strains employed
pCMV-HBV-LE- (CMV-HBV) is an HBV over-length genomic
expression vector containing 1.2 copies of the HBV(adw2) genome
(Genbank X02763.1) downstream of the CMV promoter cloned
into pBS (Promega). Surface protein expression from this vector is
ablated by mutating the preS and S open reading frames. pCMV-
HBV(genotype D) is an analogous HBV genomic expression
construct and was a gift from Dr. Shuping Tong. For bacterial
expression, codon-optimized cDNA sequences for HRHPL
(genotypes A, B, C, D, and H) were cloned by gene synthesis
(Genscript) between the NcoI and EcoRI sites into pTrcHis2B
(Invitrogen) with a C-terminal hexahistidine tag. HRHPL contains
HBV genotype D (Genbank V01460) polymerase residues 684–
845. The human RNAseH1 gene (NP_002927.2) was cloned with
an N-terminal hexahistidine-tag between the BamHI and XhoI
sites of pRsetB (Invitrogen) by gene synthesis.
RNAseH expression and enrichment
HRHPL and human RNAseH1 were expressed in E. coli BL21
codon+ cells (Invitrogen). Saturated overnight bacterial cultures
were diluted 4-fold into 100 ml fresh medium and protein
expression was induced with 0.5 mM IPTG at 30uC for six hours.
The cells were lysed by sonication in lysis buffer [50 mM HEPES
pH 8.0, 800 mM NaCl, 0.1% NP40, 27.5% glycerol, 2 mM DTT
20 mM imidazole, and protease inhibitor cocktail (Sigma)].
RNAseH proteins were enriched by nickel–agarose affinity
chromatography, eluted with 350 mM imidazole, dialyzed into
50 mM HEPES pH 7.3, 300 mM NaCl, 20% glycerol, and 5 mM
DTT, and stored in liquid nitrogen.
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In vitro RNAseH assays
For the oligonucleotide-directed RNAseH cleavage assay [46],
6 ml protein extract (typical protein concentration 2.8 mg/ml) was
mixed with 0.5 mg internally 32P-labeled DRF+ RNA (nucleotides
2401–2605 of the duck HBV genome plus 60 nucleotides of
flanking sequences from pBluescript) and 3 mg oligonucleotide
D25072 or its corresponding negative control D2526+ on ice in
20 ml under the conditions in Table 1. Some reactions in Fig. 5
employed oligonucleotide D2543M-Sal or its D2453+ negative
control as indicated. The reactions were incubated at 42uC for
90 min. and terminated by addition of Laemmli protein loading
buffer and boiling. The samples were resolved by 12% SDS-
PAGE, the gels were stained with Coomassie blue to monitor
protein loading, and labeled RNA was detected by autoradiogra-
phy. Candidate inhibitors were dissolved in DMSO and added at
the indicated concentrations during assembly of the reactions.
Control reactions lacking the compounds contained DMSO as a
vehicle control. The RNAseH autoradiograms were scanned and
quantified with ImageJ. The oligonucleotides were: D2526+
(CCACATAGGCTATGTGGAAC), D25072 (GTTCCACATA
GCCTATGTGG), D2453+ (CCGCCTGATTGGACGGCTT
TTCC), and D2543M-Sal (GCAACTGTGTCGACAGCAGC
TCCGAAGGAGA).
For the fluorescent RNAseH assay, the DRF+ RNA and DNA
oligonucleotides were omitted from the RNAseH reactions and
replaced with 20 mM of the quenched fluorescent chimeric
RNA:DNA oligonucleotide RHF1; the reaction conditions were
identical to the oligonucleotide-directed reactions except that the
NaCl concentration was reduced to 130 mM. The reactions were
incubated in the dark at 42uC for 90 min. prior to termination by
addition EDTA to 10 mM and detection of fluorescence at
520 nM on Synergy 4 plate reader (Biotec, Inc.). The sequence of
the RHF1 substrate (IDT, Inc.) was: 59-56-FAM/rCrCrArCrAr-
UrArGrGrCrUrArUrGrUrGrGrArArCTTTTGTTCCACATA-
GCCTATGTGG/3IBkFQ/-39. The RNA:DNA heteroduplex in
the RHF1 substrate was the same as the heteroduplex formed by
oligo D25072 annealed to DRF+.
Cell-based HBV replication inhibition assays
Huh7 cells were maintained in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum at 37uC in 5% CO2. Cells
were seeded into 60 mm dishes and transfected at 70% confluency
with 2.6 mg of plasmids using TransIT-LT1 (Mirus, Inc.). Test
compounds were added the morning following transfection at 10
or 50 mM, and fresh medium containing the compounds was
provided every 1–2 days. Four or five days post-transfection HBV
cores were isolated by lysis of the cells in 10 mM Tris pH 7.5,
1 mM EDTA, 0.25% NP40, 50 mM NaCl, and 8% sucrose
followed by sedimentation through a 30% sucrose cushion as
described [105]. Viral DNAs were isolated from cytoplasmic core
particle preparations by proteinase K digestion followed by
phenol/chloroform extraction as described [46]. Duplicate
aliquots of the nucleic acids were treated with 2 U E. coli
DNAse-free RNAseH (Invitrogen) at 37uC for 30 min. or were
mock treated. The nucleic acid samples were resolved by
electrophoresis on 1.2% agarose gels and detected by Southern
blotting with 32P-labeled HBV DNA as a probe.
Supporting Information
Figure S1 Chemical structures of the compounds test-
ed. Compounds are named by the company/product number or
their formal names, as appropriate. The approved anti-HIV
integrase drugs Elvitegravir (#10) and Raltegravir (#11) are listed
by their common names, pharmaceutical developer’s codes, and
company/product numbers. Compound #40 is listed by its NIH
AIDS Research and Reference Reagent Program number.
(PDF)
Table S1 Residual activity in RNAseH reactions con-
ducted in the presence of 10 mM of the test compounds.
Values are normalized to vehicle control reactions containing 1%
DMSO and the error ranges are 6 the standard deviation from 3
to 7 replicate experiments.
(PDF)
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